Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

First Line ◽

Pik3ca Mutations ◽

First Line Therapy ◽

Impact of prophylactic systemic antibiotics (SA) on outcome of patients (pts) with RAS-wildtype (RAS-wt) metastatic colorectal carcinoma (mCRC) treated with cetuximab-based first-line therapy. Subgroup analysis of the german non-interventional study ERBITAG

Annals of Oncology ◽

10.1093/annonc/mdz246.053 ◽

2019 ◽

Vol 30 ◽

pp. v218

Author(s):

S.W. Sahm ◽

M.-O. Zahn ◽

C. Maintz ◽

T. Goehler ◽

J. Janssen ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Subgroup Analysis ◽

First Line ◽

Interventional Study ◽

First Line Therapy ◽

Line Therapy ◽

Systemic Antibiotics

Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma

Cancer ◽

10.1002/cncr.21411 ◽

2005 ◽

Vol 104 (9) ◽

pp. 1871-1884 ◽

Cited By ~ 28

Author(s):

Bruce E. Hillner ◽

Deborah Schrag ◽

Daniel J. Sargent ◽

Charles S. Fuchs ◽

Richard M. Goldberg

Keyword(s):

Cost Effectiveness ◽

Colorectal Carcinoma ◽

First Line ◽

First Line Therapy ◽

Cetuximab in the first-line therapy of metastatic colorectal carcinoma: not so CRYSTAL clear

Future Oncology ◽

10.2217/14796694.4.6.741 ◽

2008 ◽

Vol 4 (6) ◽

pp. 741-744 ◽

Cited By ~ 4

Author(s):

Alastair CJ Windsor ◽

Richard Cohen ◽

Long R Jiao ◽

Justin Stebbing

Keyword(s):

Colorectal Carcinoma ◽

First Line ◽

First Line Therapy ◽

Impact of surgical resection of liver metastases on outcome of patients with KRAS-wildtype exon 2 (KRAS-wt) metastatic colorectal carcinoma (mCRC) treated with a cetuximab-based first-line therapy - Interim analysis of the German non-interventional study ERBITAG

Annals of Oncology ◽

10.1093/annonc/mdw370.39 ◽

2016 ◽

Vol 27 ◽

pp. vi162

Author(s):

U. Neumann ◽

T. Goehler ◽

C. Hering-Schubert ◽

J. Janssen ◽

S. Sahm ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Liver Metastases ◽

Surgical Resection ◽

Interim Analysis ◽

First Line ◽

Interventional Study ◽

Exon 2 ◽

First Line Therapy ◽

O-020 Quality-of-life results from RAISE: randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine

Annals of Oncology ◽

10.1093/annonc/mdv235.19 ◽

2015 ◽

Vol 26 ◽

pp. iv115 ◽

Cited By ~ 3

Author(s):

R. Garcia-Carbonero ◽

R. Obermannova ◽

G. Bodoky ◽

J. Prausova ◽

T.-E. Ciuleanu ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Carcinoma ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study

P-157 A phase II study of XELOX and Cetuximab (Erbitux) as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (FLEET2)

Annals of Oncology ◽

10.1093/annonc/mdw199.151 ◽

2016 ◽

Vol 27 ◽

pp. ii46

Author(s):

S. Iwamoto ◽

S. Hazama ◽

H. Kin ◽

H. Takemoto ◽

K. Kobayashi ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

BMC Cancer ◽

10.1186/s12885-015-1685-z ◽

2015 ◽

Vol 15 (1) ◽

Cited By ~ 12

Author(s):

Hitoshi Soda ◽

Hiromichi Maeda ◽

Junichi Hasegawa ◽

Takao Takahashi ◽

Shoichi Hazama ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase ◽

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)70127-0 ◽

2015 ◽

Vol 16 (5) ◽

pp. 499-508 ◽

Cited By ~ 406

Author(s):

Josep Tabernero ◽

Takayuki Yoshino ◽

Allen Lee Cohn ◽

Radka Obermannova ◽

Gyorgy Bodoky ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Second Line ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

First Line Therapy ◽

A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study)

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2016.07.003 ◽

2016 ◽

Vol 15 (4) ◽

pp. 329-336 ◽

Cited By ~ 9

Author(s):

Shoichi Hazama ◽

Hiromichi Maeda ◽

Shigeyoshi Iwamoto ◽

Ho Min Kim ◽

Hiroyoshi Takemoto ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

First Line ◽

First Line Therapy ◽

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Patients with Kras Wild-Type Unresectable Colorectal Liver-Limited Metastases: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial (Clime Study)

Annals of Oncology ◽

10.1093/annonc/mdu333.100 ◽

2014 ◽

Vol 25 ◽

pp. iv204 ◽

Cited By ~ 2

Author(s):

S. Cai ◽

W. Zhang ◽

W. Li ◽

Y. Xu ◽

W. Gu ◽

...

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Phase Ii Clinical Trial ◽

Wild Type ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase ◽